In a year that was driven largely by significant growth in its expanded multiple sclerosis (MS) franchise, Cambridge, Mass.-based Biogen Idec Inc. reported $6.9 billion in revenue, a 26 percent increase compared to 2012, in its full year and fourth quarter 2013 financial results just released.